Upcoming Investor Conference Participation by ORIC Pharmaceuticals
In an exciting development for investors and stakeholders, ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC), a forward-thinking clinical stage oncology company, is set to participate in several significant investor events this coming November. These conferences offer a valuable platform for the company to engage with the investment community, share insights, and discuss its innovative approaches to overcoming therapeutic resistance in cancer treatment.
Guggenheim's 2nd Annual Healthcare Innovation Conference
Taking place on a prominent stage, the management team from ORIC Pharmaceuticals will participate in a fireside chat at Guggenheim's 2nd Annual Healthcare Innovation Conference. On November 11, buy-side and sell-side analysts along with healthcare professionals can expect to gain insights at 1:30 p.m. ET. This engaging forum is an excellent opportunity for both industry veterans and new entrants to uncover the latest trends in oncology.
Stifel 2025 Healthcare Conference
On November 12, ORIC will also partake in one-on-one meetings at the Stifel 2025 Healthcare Conference. These personalized discussions will allow the management team to connect directly with potential investors, discuss company strategies, and delve deeper into the unique challenges the company is addressing with their groundbreaking drug candidates.
Jefferies London Healthcare Conference
Lastly, ORIC Pharmaceuticals will be represented at the Jefferies London Healthcare Conference on November 19, participating in a fireside chat at 2:30 p.m. GMT. This international presence not only highlights ORIC's commitment to transparency but also its ambition to showcase their critical work across borders and to a global audience, emphasizing the impact of their clinical trials and innovations.
Webcasts and Replay Availability
For those unable to attend these conferences in person, ORIC will provide webcasts of the fireside chat discussions. These can be accessed through the investor relations section of ORIC's official website. It’s noteworthy that replays will remain available for 90 days after each event, ensuring that investors and interested parties can catch up on essential insights and information shared during these important discussions.
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is dedicated to enhancing patient outcomes by focusing on mechanisms of resistance to cancer therapies. Their lead product candidates include ORIC-944, an allosteric inhibitor targeting the polycomb repressive complex 2 (PRC2), aimed at treating prostate cancer, and enozertinib (ORIC-114), which is a brain-penetrant inhibitor targeting specific EGFR and HER2 mutations across various genetically defined cancers. With headquarters in both South San Francisco and San Diego, ORIC strives to lead innovations in oncology.
Contact Information
For further inquiries, interested parties can contact Dominic Piscitelli, the Chief Financial Officer of ORIC Pharmaceuticals, via email at dominic.piscitelli@oricpharma.com. Alternatively, general inquiries can be directed to info@oricpharma.com.
Frequently Asked Questions
What is ORIC Pharmaceuticals focused on?
ORIC Pharmaceuticals is focused on developing innovative treatments that address the mechanisms of therapeutic resistance in cancer.
When is ORIC participating in the upcoming investor conferences?
ORIC Pharmaceuticals will participate in various investor conferences throughout November, including events hosted by Guggenheim, Stifel, and Jefferies.
How can investors access the webcasts of the conferences?
Investors can access webcasts of the fireside chats through the investor relations section on ORIC's official website, with replays available for 90 days.
What are ORIC's lead product candidates?
ORIC's main product candidates are ORIC-944, targeting prostate cancer, and enozertinib (ORIC-114), aimed at multiple genetically defined cancers.
Who can I contact for more information regarding ORIC Pharmaceuticals?
Dominic Piscitelli, the Chief Financial Officer, is the main contact person, and inquiries can be sent to his email or the general info email at ORIC.